Eun Ju Ko1, Eo Jin Kim2, Hye Jung Cho3, Jisu Oh4,5, Han Sung Park1, Chang Soo Ryu1, Jung Oh Kim1, Hak Hoon Jun3, So Young Chong4, Jong Woo Kim6, Nam Keun Kim7. 1. Department of Biomedical Science, College of Life Science, CHA University, Seongnam, South Korea. 2. Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. 3. Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, South Korea. 4. Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, South Korea. 5. Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. 6. Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, South Korea. kjw@cha.ac.kr. 7. Department of Biomedical Science, College of Life Science, CHA University, Seongnam, South Korea. nkkim@cha.ac.kr.
Abstract
BACKGROUND: Polymorphisms of endothelial nitric oxide synthases (eNOS) have been associated with cancer susceptibility. Also, metabolic syndrome is associated with cancer malignancy. However, the effect of eNOS polymorphisms and metabolic syndrome on colorectal cancer (CRC) prognosis remains unclear. OBJECTIVE: To investigated whether three genetic polymorphisms (- 786 T > C rs2070744, 4a4b rs869109213, and 894G > T rs1799983) in the eNOS and metabolic syndrome (MetS) were associated with CRC patient survival. METHODS: We genotyped three polymorphisms of eNOS (- 786 T > C, 4a4b, and 894G > T) in 312 CRC cases from the Korean population by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. RESULTS: Although the three eNOS polymorphisms were not causative of MetS, the TT genotype of the 894G > T polymorphism was associated with a worse survival rate compared with the GG genotype in the CRC group with MetS than in the CRC group without MetS (5-years survival; adjusted HR = 54.777; 95% CI 5.073-591.487 and RFS; adjusted HR = 14.909; 95% CI 1.571-141.528). CONCLUSIONS: The eNOS polymorphisms were not associated with metabolic syndrome prevalence in CRC patients. However, our findings suggest that the eNOS 894G > T polymorphism with MetS was associated with poor clinical outcomes.
BACKGROUND: Polymorphisms of endothelial nitric oxide synthases (eNOS) have been associated with cancer susceptibility. Also, metabolic syndrome is associated with cancer malignancy. However, the effect of eNOS polymorphisms and metabolic syndrome on colorectal cancer (CRC) prognosis remains unclear. OBJECTIVE: To investigated whether three genetic polymorphisms (- 786 T > C rs2070744, 4a4b rs869109213, and 894G > T rs1799983) in the eNOS and metabolic syndrome (MetS) were associated with CRC patient survival. METHODS: We genotyped three polymorphisms of eNOS (- 786 T > C, 4a4b, and 894G > T) in 312 CRC cases from the Korean population by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. RESULTS: Although the three eNOS polymorphisms were not causative of MetS, the TT genotype of the 894G > T polymorphism was associated with a worse survival rate compared with the GG genotype in the CRC group with MetS than in the CRC group without MetS (5-years survival; adjusted HR = 54.777; 95% CI 5.073-591.487 and RFS; adjusted HR = 14.909; 95% CI 1.571-141.528). CONCLUSIONS: The eNOS polymorphisms were not associated with metabolic syndrome prevalence in CRC patients. However, our findings suggest that the eNOS 894G > T polymorphism with MetS was associated with poor clinical outcomes.
Authors: Manuel Chaves Conde; Reposo Ramirez-Lorca; Jose Miguel Esteban Lopez-Jamar; Eva Molero; Juan Andres Ramírez-Armengol; Jose Andrés Moreno Nogueira; Manuel Hidalgo Pascual; Agustin Ruiz; Carlos García Martín-Cordova; Luis Miguel Real; Jose Luis Royo Journal: Oncol Rep Date: 2006-08 Impact factor: 3.906
Authors: Jeehyeon Bae; In Jai Kim; Seung Ho Hong; Jung Hoon Sung; Sang Wook Lim; Dong Hoon Cha; Yong Wook Cho; Doyeun Oh; Nam Keun Kim Journal: Exp Ther Med Date: 2010-07-01 Impact factor: 2.447
Authors: Juan P Casas; Gianpiero L Cavalleri; Leonelo E Bautista; Liam Smeeth; Steve E Humphries; Aroon D Hingorani Journal: Am J Epidemiol Date: 2006-10-03 Impact factor: 4.897